

Huntington Disease (HD)

BN40697 - A study to look at tominersen safety over 15 months in people with Huntington's disease

An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

Trial Status
Completed

Trial Runs In
4 Countries

Trial Identifier
NCT03342053 ISIS 443139-CS2
BN40697

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

Trial Summary:

This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7234292 administered intrathecally to adult patients with Huntington's Disease.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT03342053 ISIS 443139-CS2 BN40697
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
#25 Years

Healthy Volunteers
No

Inclusion Criteria:

- Must have completed dosing in ISIS 443139-CS1

Exclusion Criteria:

ForPatients

by Roche

- Any new condition or worsening of existing condition that could make the patient unsuitable for participation or interfere with the patient participating in and/or completing the study